Connect Biopharma Holdings Ltd
No SEC Form 4 filings for $CNTB in the last 30 days.
See all $CNTB insider activity →Connect Biopharma's stock fell 33.6% to $1.145 after its Phase 2 asthma drug trial failed to meet the primary endpoint, despite showing some positive results. The company's drug, rademikibart, did not achieve statistical significance in reducing treatment failure rates. Analysts had previously set a $7.00 price target. The broader market also declined slightly.
Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT stud
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CNTB (Connect Biopharma Holdings Ltd). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CNTB coverage spans market movers, financial news and earnings.
Negative trial data triggered a sharp sell‑off, pushing the stock to its 52‑week low.
Upcoming data could be a catalyst for the stock.
The filing is a clinical and funding runway update that can reprice probability-weighted Phase 2 outcomes and Phase 3 planning.
Upcoming topline timing provides a forward catalyst for trading, but no new efficacy/safety data is disclosed.
Enrollment completion reduces trial execution risk and sets a clear catalyst window for topline readout and potential Phase 3 alignment discussions.
AlphAI scores every news story that mentions CNTB with an AI model for sentiment and relevance, and aggregates insider trades from Connect Biopharma Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Connect Biopharma's stock fell 33.6% to $1.145 after its Phase 2 asthma drug trial failed to meet the primary endpoint, despite showing some positive results. The company's drug, rademikibart, did not achieve statistical significance in reducing treatment failure rates. Analysts had previously set a $7.00 price target. The broader market also declined slightly.
2 min readModular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
3 min readConnect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT stud
5 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readConnect Biopharma (Nasdaq: CNTB) said it has completed enrollment in its Phase 2 Seabreeze STAT Asthma study of rademikibart (adjunct to standard of care) for acute asthma exacerbations in patients with type 2 inflammation; it enrolled 160 participants. The company expects topline data in early September 2026, plans to complete COPD enrollment this month, and aims to align on a Phase 3 program with the FDA later this year.
4 min readHuang James purchased 150,000 indirectly-held shares of Connect Biopharma Holdings Ltd (CNTB) at $2.48 ($0.37M total) on 2026-05-29.
1 min readConnect Biopharma Holdings Ltd director James Huang has filed an initial Form 3, indicating an indirect beneficial ownership of 12,000,000 Ordinary Shares through Panacea Venture Healthcare Fund II, L.P. While Huang may be deemed to share beneficial ownership due to his ownership chain with entities related to the fund, he explicitly disclaims such beneficial ownership, clarifying that the holding is at the fund level. This filing provides transparency regarding significant shareholdings linked to company leadership.
2 min readRedChip Companies will broadcast interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on its "RedChip Small Stocks, Big Money™" program on Bloomberg TV. The show will air this Saturday, November 15, at 7 p.m. ET. Interviews will feature the CEOs discussing advancements in treating severe respiratory diseases and expanding portfolios of utility-scale battery energy storage systems, respectively.
2 min readSAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( "Connect Biopharma", "Connect", or the "Company" ) , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that ...
2 min readSAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( NASDAQ:CNTB ) ( "Connect Biopharma", "Connect", or the "Company" ) , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that ... ET.
2 min read
